The following is the summary of the evidence for the use of Ivermectin to treat COVID-19 as compiled by the Front-Line COVID-19 Critical Care Alliance.

Formed by leading critical care specialists in March 2020, at the beginning of the Coronavirus pandemic, the ‘Front Line COVID-19 Critical Care Alliance’ is now a 501(c)(3) non-profit organization dedicated to developing highly effective treatment protocols to prevent the transmission of COVID-19 and to improve the outcomes for patients ill with the disease.

We are dedicated to
Reviewing all emerging published medical literature on COVID-19 from in-vitro, animal, clinical, and epidemiologic studies.
Developing effective treatment protocols for COVID-19 that evolve by incorporating newly identified, applicable therapeutic and pathophysiologic insights.
Educating physicians on safe and effective treatment approaches to all phases of COVID-19, from disease prevention strategies to the use of our combination-based therapy protocols in both early-stage (I-MASK+) and hospitalized patients (MATH+).
Improving outcomes for people impacted by COVID-19 disorders through preventive and treatment strate­gies designed to optimize health.
Teaching the public ways to prevent transmission of the virus and to advocate for the best possible care.
Coordinating and accelerating the formation of research studies that will support effective prevention and therapeutic treatments for all impacted by COVID-19.
We accomplish these goals by sponsoring high quality medical education for both the public and health care providers, via the publication of scientific manuscripts, media interviews, and medical lectures for medical providers and the public.

SOURCE: https://covid19criticalcare.com/wp-content/uploads/2021/08/SUMMARY-OF-THE-EVIDENCE-BASE-FINAL.pdf